Biomedical Engineering
-
VISE symposium explores interoperative fluorescence to light up tumors
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreDec. 18, 2017
-
Vanderbilt researchers win an R&D100 Award for MultiWell MicroFormulator
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreDec. 13, 2017
-
Tech transfer course gives grad students real-world journey
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreDec. 9, 2017
-
Nashville Mayor gives philosophy lesson to Vanderbilt engineering students
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreDec. 1, 2017
-
Faculty partnerships explored by Army Research Lab’s chief scientist
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreNov. 30, 2017
-
Clark Scholars dinner brings together students, visionary donor
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreNov. 27, 2017
-
Riding an old gray mare, BME student rounds up rodeo wins
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreNov. 17, 2017
-
Shining a light on the nervous system to thwart disease
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreNov. 16, 2017
-
BME PhD shifts to sepsis cure after dramatic end to pro cycling career
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreNov. 3, 2017
-
Grand opening of nanoscale research facilities wows crowd
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreOct. 27, 2017